Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Feb 29, 2016
SAN DIEGO, Feb. 29, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the fourth quarter and full year ended December 31, 2015, and provided a corporate update. "Arena took a number of important steps in 2015, including initiating two Phase 2 clinical trials, partnering two of our programs, ...
Feb 23, 2016
SAN DIEGO, Feb. 23, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Monday, February 29, 2016, to discuss fourth quarter and full year 2015 financial results and provide a corporate update. Arena will issue a press r...
Jan 12, 2016
INGELHEIM, Germany, and SAN DIEGO, Jan. 12, 2016 /PRNewswire/ -- Boehringer Ingelheim and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that they have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an undisclosed G protein-coupled receptor (GPCR), which belongs to the group of orphan CNS r...
Jan 7, 2016
SAN DIEGO, Jan. 7, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2016, at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time), at The Westin St. Francis Hotel in San Fr...
Dec 1, 2015
WOODCLIFF LAKE, N.J. and SAN DIEGO, Dec. 1, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the CAMELLIA-TIMI 61 study has reached its target enrollment of 12,000 patients at more than 470 sites in eight countries. The CAMELLIA-TIMI 61 outcomes study is designed to evaluate the impact of long-term...
Nov 30, 2015
WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 30, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for an extended release formulation of lorcaserin. If approved, the extended release formulation will offe...
Nov 24, 2015
SAN DIEGO, Nov. 24, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Piper Jaffray 27th Annual Healthcare Conference on Wednesday, December 2, 2015, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), at The New York Palace Hotel in New Yo...
Nov 19, 2015
SAN DIEGO, Nov. 19, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company will host an Analyst & Investor Day on Thursday, December 3, 2015, from 12:00 p.m. to 3:00 p.m. Eastern Time (9:00 a.m. to 12:00 p.m. Pacific Time) in New York City. The event will focus on Arena's internally discovered resear...
Nov 10, 2015
SAN DIEGO, Nov. 10, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the third quarter ended September 30, 2015, and provided a corporate update. "On October 27, we announced a plan to improve efficiencies and reduce costs as we chart a new course for Arena with our refocusing effort," said...
Nov 4, 2015
SAN DIEGO, Nov. 4, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Tuesday, November 10, 2015, to discuss third quarter 2015 financial results and provide a corporate update. Arena will issue a press release with its...
Nov 2, 2015
WOODCLIFF LAKE, N.J., and SAN DIEGO, Nov. 2, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that six posters regarding lorcaserin HCl data will be presented during ObesityWeekSM. Hosted by The Obesity Society and the American Society for Metabolic and Bariatric Surgery, the meeting is taking place Nov...
Oct 29, 2015
SAN DIEGO, Oct. 29, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of patient dosing in a Phase 1b multiple-ascending dose clinical trial of APD371, a selective and potent agonist of the cannabinoid 2 (CB2) receptor. This randomized, double-blind, placebo-controlled Phase 1b clinical trial will...
Oct 27, 2015
SAN DIEGO, Oct. 27, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced plans to improve efficiencies and reduce costs as it focuses on the advancement of its research and development priorities. Arena intends to focus on its key strengths by concentrating near-term activities and resources primarily on: ...
Oct 27, 2015
SAN DIEGO and WOODCLIFF LAKE, N.J., Oct. 27, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Patent and Trademark Office granted Arena US Patent No. 9,169,213, entitled "Method of Weight Management," covering BELVIQ® (lorcaserin HCl) for chronic weight management. "This patent ...
Oct 5, 2015
SAN DIEGO, Oct. 5, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that, at the request of the Board of Directors, Jack Lief, Arena's President and Chief Executive Officer, has retired from the company, including its Board of Directors. Dr. Harry F. Hixson, a director of Arena since 2004, has been appointed to serve ...
Page: First Previous
...
...
Next Last
 
= add release to Briefcase